Orient Biotech(SH:688298) Xin Lang Cai Jing·2025-10-31 03:55Group 1 - The core point of the article highlights the recent performance of Dongfang Biological, which saw a 5.15% increase in stock price, reaching 26.13 yuan per share, with a total market capitalization of 5.268 billion yuan [1] - Dongfang Biological, established on December 1, 2005, specializes in the research, production, and sales of in vitro diagnostic products, with 97.99% of its revenue coming from diagnostic reagents [1] - The company has a trading volume of 1.05 billion yuan and a turnover rate of 2.01% [1] Group 2 - From the perspective of major shareholders, the Rongtong Health Industry Flexible Allocation Mixed A/B Fund (000727) reduced its holdings by 1.7001 million shares in the third quarter, now holding 2.8 million shares, which represents 1.39% of the circulating shares [2] - The fund has achieved a year-to-date return of 13.2% and a one-year return of 8.7%, ranking 5437 out of 8154 and 6141 out of 8046 respectively [2] - The fund manager, Wan Minyuan, has a tenure of 9 years and 69 days, with the fund's total asset size at 5.957 billion yuan [3] Group 3 - The Rongtong Health Industry Flexible Allocation Mixed A/B Fund has Dongfang Biological as its tenth largest holding, accounting for 2.98% of the fund's net value [4] - The fund's floating profit from its investment in Dongfang Biological is approximately 3.584 million yuan [4]